# Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial

> **Newsylist Open Intelligence Dossier** · First detected: 2026-11-17 15:29 UTC · Category: Business · Sources: 5 · Current Velocity: 13.98

## Intelligence Brief
&quot;Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial&quot; developed substantial multi-source reporting across the Business sector, tracked across 5 distinct newsrooms by Newsylist.


Key reporting was led by GlobeNewswire, Fierce Biotech, Reuters and Yahoo Finance. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Sellas’ experimental blood cancer immunotherapy reduced risk of death in cl?
Coverage spiked when 5 independent newsrooms published 5 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| GlobeNewswire | SELLAS Life Sciences Announces Positive Pivotal Phase 3 | 2026-11-17 12:04 | [Source Link](https://news.google.com/rss/articles/CBMi7AJBVV95cUxOVWsyRXFpV2VSQkJtbGZjbUI2ZE05UG5HQ2puc2VJTVI2R2dmNGpNQnRzb04zQmgxS1dvQ2RCT05waURORkdsX201SFc4a0pDQ0tZNHFMM0ZqU0xyNjhKN01DYXdOZ0RGZy05UE41XzVybl91UklHQ3dwRWlwclhOcE9OOWt0dHVVRVotdklfZDNwdXJLdlZjSlRrWm9ZaXZRMkJycEhsVnFhMXBuUmJSQmxieWpWSGRfVWhHS1NGOW5nbnB6M2pWY2REdzg5MFNPYW03clF1c1YySmZRLU1VVExTampyQzFUeTg3dDZQV3hYa0N0NkdENWVlSHFVTkU0NWktUE5ESjI2YVhJRXhTOXJOQTFqeTVfQ1c4aVlxakkzSGtoam9HNWd3OXV1NDAtaDR6S2F2TmowWDFnMmR5bGRtOEUtUjFudGV4MnR5MFFuQkVrbWl) |
| Fierce Biotech | Sellas marks 9-month survival benefit in late-stage leukemia vaccine study | 2026-11-17 12:04 | [Source Link](https://news.google.com/rss/articles/CBMisgFBVV95cUxOOHp5QS1VOElwWFlEUHNXWTdRenFMZ1NJd2I2NzdBdUJQRkxNaF9yYl9Scmp4RU5EUzhDbHFUX0lTZF9OcTNWTzdSYXJEY3BvemtfZ1ZNS3l1Q3hMVkhhVXh6UmF6Z0FhdEN4YTR5N2ZGbDVMOVIxNnFfbDdjNFREZGU4X0Z1eHNfSlNvdFJjNGZHajdILTBiV0tXNUlYVmNfM3dhWE9uWGRacDVGQ3ZGWkJ3?oc=5) |
| Reuters | Sellas' vaccine extends survival in blood cancer trial | 2026-11-17 12:04 | [Source Link](https://news.google.com/rss/articles/CBMiyAFBVV95cUxQa3FEUmx6RWVvS3AzWXBDaDZvTUdmdUo4RjlwWmlrdDEyYUxrNUxVVTFybndQRGExYVA5SWdmWndNZkJkR1pkcVdvdVVtX21qZjNsZUFfd0VnMnRTTjVRTEtVSGpsNHk5R0N5eHFxRlROQmpCYk1TdVl5bm9qZ1AySlVNN1lvUVZYb1FRUVdFWDVUZVJFcExyYWNVb3VQWjZNLXZSNGQyLW9TeEJqWTdWSFJ2eVd6R3VON29KclpPTEFBTk55akk2aQ?oc=5) |
| Yahoo Finance | Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial | 2026-11-17 12:04 | [Source Link](https://news.google.com/rss/articles/CBMikAFBVV95cUxPMGNtVWtXSHR5dk14UVVwLXhIb2xfVzZoa09nZGRJMmtiQ1FfaTZacFJUSXdIMHloQUhSak1DWkJHSDBwOElPLS1oLVA1UUN1elZyc0dxdUFTc0NtR2V4YUZEaVkwNG5Odlg5bXJKcUY5NGhPNzNKR0RlakR3bDNfNjNpSnhLY3pweWpnTUNiYkI?oc=5) |
| STAT | Sellas’ experimental blood cancer immunotherapy reduced risk of death in clinical trial | 2026-11-17 12:04 | [Source Link](https://news.google.com/rss/articles/CBMimgFBVV95cUxPeS0wYzFpWVF6bzNsZzRnWGlNYnFfWnQ0LWdXVi1lZGFUQlBhN2ZrNi0yMzZVQWY1Z2lzRnU3SHFveFh4ZVctVE83MkIwVFJJUFQtSGpRMTZvaWF0SnV1eDVadExIVHpmM1NiTDdkR1FodU9yQ3RWbmZyVlIteWpHX2daRTdFSGFnMHhJVE04d1ZnTjJqbDhGV0ln?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-11-17/sellas-experimental-blood-cancer-immunotherapy-reduced-risk-of-death-in*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*
